![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() by Staff Writers Hong Kong (AFP) July 24, 2018
Hong Kong clinics said they have seen a surge in demand for children's vaccines Tuesday after a safety scandal rocked mainland China. The crisis stemmed from falsified production data of a rabies inoculation by a major mainland manufacturer. But vaccines against diphtheria, tetanus and whooping cough, given to babies and infants, were also found to be sub-standard, with doses already sold and administered. The mounting scandal has raised questions about the safety of China's entire vaccine industry and has led some parents to seek treatment in semi-autonomous Hong Kong. The city already has a reputation for safer medication than mainland China and has seen a rush on its products in the past after health scandals over the border. One private Hong Kong clinic in the commercial hub of Tsim Sha Tsui said it had received hundreds of calls and messages, around six times the normal rate of enquiries, since the scandal broke over the weekend. Manager Jacky Ho described the demand as "explosive", saying it was mostly from mainland Chinese parents looking for vaccines imported from countries other than China. "The closest place for them to get the vaccines is Hong Kong," said Ho, who added the clinic's inoculations come from England, France and the United States. A woman who gave her name as Mrs Yin, from Shenzhen in southern mainland China, said she had brought her two-year-old son to the clinic for three different types of vaccinations. "We are worried about the quality of domestic vaccines," said Yin, who said she had spent HK$5,000 ($640) on the inoculations: PCV13 which protects against pneumococcal bacteria, Japanese encephalitis and the ACWY vaccination to protect against meningitis. She said she had made an appointment for the PCV13 jab before the crisis broke, but had added the other inoculations for good measure after hearing of the scandal. Another man from Guangdong in southern China, who gave his surname Chan said he had brought his one-year-old son to a private clinic in the same area for the PCV13 inoculation after making an appointment two months ago. "Now I feel very lucky that we came here. We have more confidence in Hong Kong," he told AFP. Private hospital Hong Kong Sanatorium said it had seen a rise in enquiries and had contacted suppliers to ensure "a stable supply of vaccines to meet the needs of patients in coming days" in a statement to AFP. Hong Kong's health department said it would closely monitor the supply of vaccines to both public and private healthcare sectors but described it as "stable" for now. Scarlett Pong, president of the city's Pharmaceutical Society, added that there was an established information network which connected Hong Kong clinics with mainland Chinese customers. "There are agents helping them make appointments and who know where to get information like which doctor to use," she told AFP. yz-ey-ec-lm/jta
![]() ![]() Chinese president calls latest pharma scare "vile" Shanghai (AFP) July 23, 2018 Chinese President Xi Jinping on Monday described a vaccine safety scandal as "vile" and "shocking" as police opened a criminal investigation into the firm responsible and its management. Xi, on a trip to Africa, echoed the calls from Premier Li Keqiang for a thorough investigation and stern action over the latest safety scare to hit the pharmaceutical industry. "Changchun Changsheng Biotechnology's illegal production of vaccines is vile in nature and shocking," Xi said, according to state broadc ... read more
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |